sciencesite.blogg.se

Anti human fgfr3 antibody cross reactivity
Anti human fgfr3 antibody cross reactivity




anti human fgfr3 antibody cross reactivity

Isoform 2 is detected in epithelial cells. In 20- to 22-week old fetuses it is expressed at high level in kidney, lung, small intestine and brain, and to a lower degree in spleen, liver, and muscle. Very low or no expression in spleen, heart, and muscle.

anti human fgfr3 antibody cross reactivity

Multiple alternatively spliced transcript variants encoding different isoforms have been noted for this gene.Expressed in brain, kidney and testis. Mutations in this gene are associated with Crouzon syndrome, Pfeiffer syndrome, Craniosynostosis, Apert syndrome, Jackson-Weiss syndrome, Beare-Stevenson cutis gyrata syndrome, Saethre-Chotzen syndrome, and syndromic craniosynostosis. This particular family member is a high-affinity receptor for acidic, basic and/or keratinocyte growth factor, depending on the isoform. The extracellular portion of the protein interacts with fibroblast growth factors, setting in motion a cascade of downstream signals, ultimately influencing mitogenesis and differentiation. A full-length representative protein consists of an extracellular region, composed of three immunoglobulin-like domains, a single hydrophobic membrane-spanning segment and a cytoplasmic tyrosine kinase domain. FGFR family members differ from one another in their ligand affinities and tissue distribution. The protein encoded by this gene is a member of the fibroblast growth factor receptor family, where amino acid sequence is highly conserved between members and throughout evolution.Vermeulen JF, Kornegoor R, van der Wall E, van der Groep P, van Diest PJ.PLoS One. Differential expression of growth factor receptors and membrane-bound tumor markers for imaging in male and female breast cancer.The expression of fibroblast growth factor receptors during early bovine conceptus development and pharmacological analysis of their actions on trophoblast growth in vitro.Katano H, Yamada KJ Stroke Cerebrovasc Dis. Upregulation of ANGPTL4 Messenger RNA and Protein in Severely Calcified Carotid Plaques.Lee HJ, Seo AN, Park SY, Kim JY, Park JY, Yu JH, Ahn JH, Gong GAnn Surg Oncol. Low Prognostic Implication of Fibroblast Growth Factor Family Activation in Triple-negative Breast Cancer Subsets.Mannose phosphate isomerase regulates fibroblast growth factor receptor family signaling and glioma radiosensitivity.Ĭazet A, Charest J, Bennett DC, Sambrooks CL, Contessa JNPLoS One.Grygielewicz P, Dymek B, Bujak A, Gunerka P, Stanczak A, Lamparska-Przybysz M, Wieczorek M, Dzwonek K, Zdzalik DGastric Cancer.

anti human fgfr3 antibody cross reactivity

  • Epithelial-mesenchymal transition confers resistance to selective FGFR inhibitors in SNU-16 gastric cancer cells.
  • Yoon G, Lee H, Kim JH, Hur K, Seo AN.Tumour Biol.
  • Clinical significance of fibroblast growth factor receptor 2 expression in patients with residual rectal cancer after preoperative chemoradiotherapy: relationship with KRAS or BRAF mutations and MSI status.
  • Conserved roles of fibroblast growth factor receptor 2 signaling in the regulation of inner cell mass development in bovine blastocysts.Īkizawa H, Nagatomo H, Odagiri H, Kohri N, Yamauchi N, Yanagawa Y, Nagano M, Takahashi M, Kawahara M.Mol Reprod Dev.
  • Interactions between FGFR2 and RSK2-implications for breast cancer prognosis.Ĭzaplinska D, Mieczkowski K, Supernat A, Skladanowski AC, Kordek R, Biernat W, Zaczek AJ, Romanska HM, Sadej R.Tumour Biol.
  • Turczyk L, Kitowska K, Mieszkowska M, Mieczkowski K, Czaplinska D, Piasecka D, Kordek R, Skladanowski AC, Potemski P, Romanska HM, Sadej R.Neoplasia.
  • FGFR2-Driven Signaling Counteracts Tamoxifen Effect on ERα-Positive Breast Cancer Cells.
  • Marcin Braun, Dominika Piasecka, Mateusz Bobrowski, Radzislaw Kordek, Rafal Sadej, Hanna M Romanska.Diagnostics (Basel).
  • A 'Real-Life' Experience on Automated Digital Image Analysis of FGFR2 Immunohistochemistry in Breast Cancer.
  • Kamil Mieczkowski, Kamila Kitowska, Marcin Braun, Barbara Galikowska-Bogut, Monika Gorska-Arcisz, Dominika Piasecka, Konrad Stawiski, Anna J Zaczek, Dariusz Nejc, Radzisław Kordek, Hanna M Romanska, Rafal Sadej.Mol Oncol.
  • FGF7/FGFR2-JunB signalling counteracts the effect of progesterone in luminal breast cancer.





  • Anti human fgfr3 antibody cross reactivity